Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results